VivoSeq
Other

Drug Interactions

0

Pipeline Programs↗

10

Active Trials↗

43

Companies Involved↗

Drug Interactions is an early-stage landscape with 0 programs across 43 companies. The most active players are Daewoong Pharmaceutical Co. LTD., AstraZeneca, Boryung Pharmaceutical Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalBoryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd

0 programs

PreclinicalCSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

0 programs

PreclinicalEisai logo

Eisai

0 programs

PreclinicalHanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

129

clinical trials

Completed109 · 84%
Unknown status6 · 5%
Recruiting4 · 3%
Active, not recruiting3 · 2%
Not yet recruiting3 · 2%
Terminated2 · 2%
Other2 · 2%

Clinical Trials

Trial Activity

129 trials

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
Recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07128888·60 enrolled
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
Recruiting·WWashington State University·Phase 1·NCT06693960·16 enrolled
Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions
Recruiting·EEnyo Pharma·Phase 1·NCT07251153·40 enrolled
Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering
Recruiting·UUniversity of California, San Diego·Approved·NCT06865885·100 enrolled
Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women
Active, not recruiting·TThai Red Cross AIDS Research Centre·N/A·NCT04590417·20 enrolled
Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men
Active, not recruiting·TThai Red Cross AIDS Research Centre·N/A·NCT04593680·20 enrolled
Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-HCR21 and IY-MIC
Active, not recruiting·IIl-Yang Pharm. Co., Ltd.·Phase 1·NCT06471868·60 enrolled
Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
Not yet recruiting·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 1·NCT06644404·34 enrolled
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
Not yet recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 1·NCT07229716·20 enrolled
A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
Not yet recruiting·EEndeavor Biomedicines, Inc.·Phase 1·NCT07454291·57 enrolled
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
Completed·MMakerere University·Phase 2·NCT04385719·24 enrolled
A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT06173596·60 enrolled
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
Completed·Biogen logoBiogen·Phase 1·NCT06264440·18 enrolled
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole
Completed·IIl-Yang Pharm. Co., Ltd.·Phase 1·NCT05237297·72 enrolled
Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects
Completed·RRepros Therapeutics Inc.·Phase 1·NCT00741468·18 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)